Trial Profile

An Open-label, Multicenter Trial of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of Tuvusertib (M1774) in Participants With Metastatic or Locally Advanced Unresectable Solid Tumors (DDRiver Solid Tumors 301)

Status: Active, no longer recruiting

Phase of Trial: Phase I

Latest Information Update: 28 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tuvusertib (Primary) ; Niraparib
Indications Advanced breast cancer; Ovarian cancer; Prostate cancer; Solid tumours
Focus Adverse reactions; First in man; Pharmacokinetics; Therapeutic Use
Acronyms DDRiver Solid Tumors 301
Sponsors EMD Serono Research & Development Institute

26 Nov 2024 Planned End Date changed from 30 Jan 2025 to 30 Jan 2026.
26 Nov 2024 Planned primary completion date changed from 30 Jan 2025 to 30 Jan 2026.
17 Jun 2024 Planned End Date changed from 19 Jul 2024 to 30 Jan 2025.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com